|
Prognosis after local recurrence in vulvar cancer: A subset analysis of the AGO-CaRE-1 study. |
|
|
Honoraria - Jenapharm; Medac; PharmaMar |
Travel, Accommodations, Expenses - Medac |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Roche Pharma AG |
Consulting or Advisory Role - Roche Pharma AG |
Research Funding - Roche Pharma AG (Inst); Roche Pharma AG (Inst); Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; PharmaMar; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Janssen-Cilag; Jenapharm; Medac; PharmaMar; Roche Pharma AG |
Consulting or Advisory Role - AstraZeneca; Janssen-Cilag; Medac; Roche Pharma AG |
Research Funding - Medac; PharmaMar; Roche Pharma AG |
Travel, Accommodations, Expenses - Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; GlaxoSmithKline; Janssen-Cilag; Jenapharm; Medac; PharmaMar; Roche/Genentech; Teva |
Consulting or Advisory Role - AstraZeneca; Janssen-Cilag; Medac; Merck Sharp & Dohme; Roche; Tesaro |
Research Funding - AstraZeneca; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Janssen-Cilag; Medac; PharmaMar; Roche; Tesaro |